The need for new treatments for Parkinson's is very clear.
“All attempts to slow the progression of Parkinson’s have thus far failed,” Professor Dario Alessi, a biochemist who works at the University of Dundee in Scotland, wrote in an email to the New York Times. Professor Alessi also emphasized that the most commonly used Parkinson’s drug currently, called Levodopa, was initially used in the clinic in 1967.
“However, in recent years, our knowledge of the genetics and biology underlining Parkinson’s disease has exploded,” Professor Alessi wrote. “I feel optimistic and it is not unrealistic that with a coordinated research effort, major strides towards better treating Parkinson’s disease can be made.”